TS Picks: September 8, 2015

Pharma edition

Jef Akst
Jef Akst

Jef Akst was managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.

View full profile.

Learn about our editorial policies.


Selections from The Scientist’s reading list:

  • Swapping out some of the hydrogen atoms in existing drugs with heavier deuterium molecules could lead to drugs that resist metabolic clearance, staying in the body for longer. This is the hope of several biotechs currently developing such “deuterated” pharmaceuticals, the first of which is currently under review by the US Food and Drug Administration (FDA), The Economist reported last week (September 3).

  • Last week (September 3), Novartis announced that it will soon market a biosimilar drug called Zarxio, comparable to Amgen’s Neupogen for neutropenia, or loss of white blood cells caused by cancer or a bone marrow transplant. The copycat drug will cost 15 percent less than Neupogen. “Zarxio’s launch will mark the first commercial offering of a biosimilar in the U.S.,” The Wall Street Journal reported. “[B]iosimilars will change the competitive landscape.”

  • Economist Andrew Lo of MIT and his...

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?